New Delhi, Sept. 28 -- Dr Lal PathLabs is buying 70% of SN Genelab for Rs.168 crore. There's also an additional Rs.31.5 crore it will pay if SN Genelab hits certain performance targets.

SN Genelab's fiscal year (FY26) revenue was Rs.58 crore, which is just 2% of Dr Lal's revenue last year. So, an immediate boost to Dr Lal can be ruled out.

As per Nomura Research, SN Genelab's acquisition may be marginally earnings per share dilutive for Dr Lal in the near term.

However, SN Genelab's testing capabilities could gain wider reach through Dr Lal's network over time, potentially boosting growth. Dr Lal has a huge network of hospitals, doctors, and patients across India (both B2B and B2C). The deal also helps strengthen Dr Lal's reach in west...